HENDERSON, NV / ACCESSWIRE / October 2, 2018 / The global stem cell market is expected to reach US 270.5 Billion by 2025, while increasing at a compound annual growth rate of 13.8% during the period from 2017 to 2025. All this comes from a report published by Transparency Market Research. From a global perspective, North America accounts for a leading share in the market due to rising instances of chronic diseases, increasing research investment and technological progress. The stem cells market in North America is projected to be worth USD 167.33 Billion by 2025.
The lead analyst of the report explains, "The growing prevalence of chronic diseases and increasing investments of pharmaceutical and biopharmaceutical companies in stem cell research are the key driving factors for the stem cells therapeutics market. The growing number of stem cell donors improved stem cell banking facilities, and increasing research and development are other crucial factors serving to propel the market."
One stem cell play we like a lot is BioRestorative Therapies, Inc.,(BRTX) a life sciences company focused on stem cell-based therapies, recently reported positive findings from Defined Health, which was engaged by the Company to conduct an independent review of BRTX-100, the Company's lead cell therapy candidate designed to treat chronic Lumbar Disc Disease (cLDD). Defined Health is a business development and strategy consulting firm that has worked with many of the leading companies in the pharmaceutical, biotech and healthcare industries for over 25 years.
The Company plans to use the results of the review to further refine its planned activities around BRTX-100, including potential licensing, co-development and commercialization activities.
Since announcing this news, the Company has seen increased interest from investors this summer, which could lead to a major move in the near future.
Prior to clinical trial results may be the ideal time to take a look at BRTX.
These here are a few stem cell plays you should pay attention to BioRestorative Therapies, Inc. (BRTX), Insys Therapeutics, Inc. (INSY), Athersys, Inc. (ATHX), Arena Pharmaceuticals, Inc. (ARNA) and CRISPR Therapeutics AG (CRSP).
BioRestorative Therapies, Inc. (BRTX)
Market Cap: $14.52M Share Price: $1.80
BioRestorative Therapies, Inc. (BRTX), a life sciences company focused on stem cell-based therapies, just announced that the Company has entered into a one-year material transfer agreement with the University of Pennsylvania providing the University access to the Company's proprietary brown adipose tissue fat cells.
Insys Therapeutics, Inc. (INSY)
Market Cap: $726.85M Share Price: $9.79
INSYS Therapeutics, Inc. (INSY), a leader in the development, manufacture, and commercialization of pharmaceutical cannabinoids and spray technology, announced that it has signed a definitive license agreement with Lunatus for commercialization of SUBSYS® (fentanyl sublingual spray) in eight countries in the Middle East.
In May, the two companies announced their intent to form an exclusive partnership. Today's announcement confirms that the definitive agreement has been executed, making Dubai-based Lunatus the exclusive licensee and authorized agent for SUBSYS in the territory, which comprises Bahrain, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, and the United Arab Emirates.
Athersys, Inc. (ATHX)
Market Cap: $299.34M Share Price: $2.15
Athersys, Inc. (ATHX) Chairman and CEO Gil Van Bokkelen will present at the annual Cell & Gene Meeting on the Mesa to be held October 3rd-5th in La Jolla, California.
Dr. Van Bokkelen will provide a brief overview of the Athersys' clinical pipeline, focusing on the ongoing Phase 3 trial of MultiStem® cell therapy for the treatment of ischemic stroke that has received Fast Track and RMAT designation from the U.S. Food and Drug Administration, positive scientific advice from the European Medicines Agency, and is being conducted under a Special Protocol Assessment (SPA).
Arena Pharmaceuticals, Inc. (ARNA)
Market Cap: $2.31B Share Price: $47.00
Arena Pharma announced positive topline results from its Phase 2a trial of olorinab, an investigational, peripherally restricted, highly selective, full agonist of the cannabinoid receptor 2 (CB2) in development for the treatment of gastrointestinal pain.
Phase 2a Trial Design
This was a randomized, open-label, 8-week study investigating two doses of olorinab (25 mg and 100 mg) administered TID (three times daily). All patients were diagnosed with quiescent to mild active Crohn's disease associated with chronic abdominal pain defined as a baseline Average Abdominal Pain Score (AAPS) ≥4. Fourteen patients were enrolled with a mean baseline AAPS of 5.6.
CRISPR Therapeutics AG (CRSP)
Market Cap: $2.25B Share Price: $43.89
CRISPR Therapeutics (CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, announced the pricing of an underwritten public offering of 4,210,526 common shares at a public offering price of $47.50 per share, before underwriting discounts. In addition, underwriters have a 30-day option to purchase up to an additional 631,578 common shares at the public offering price less the underwriting discount. CRISPR Therapeutics anticipates its gross proceeds from the offering, before deducting the underwriter discounts and commissions and other offering expenses, to be approximately $200 million, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on or about September 25, 2018, subject to customary closing conditions.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns Microcapspeculators.com, is not registered with Finra or any other financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] Microcapspeculators.com does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns Microcapspeculators.com, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated one thousand dollars cash for this article and nineteen thousand dollars total by Regal Consulting. LLC, for news commentary articles for BRTX. BRTX and Regal Consulting, LLC was given an opportunity to edit information included in this article. This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information. ACR Communications, LLC. and the hiring party Regal Consulting, LLC. may buy or sell additional shares of BRTX in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.
For Full Legal Disclaimer Click Here.
Regal Consulting, LLC. For Full Legal Disclaimer Click Here.
SOURCE: ACR Communications LLC